Answers are grounded in this paper and cite their sources.
Experimental research shows mesoporous silicon microparticles improve immune response in mice and enhance IFN-γ production in human PBMCs, suggesting novel vaccine adjuvant potential.
Abstract Silica-based materials have garnered interest as adjuvants due to their capacity to potentiate immune responses. In this study, we assess the immunogenicity and protective efficacy of heteromorphous mesoporous silicon microparticles (MSMPs) as an adjuvant in the context of SARS-CoV-2 vaccination. MSMPs conjugated with the S1 subunit of the spike protein (MSMPs-S1) induced a robust and sustained humoral immune response in BALB/c mice, comparable to that elicited by aluminum-based adjuvants. Following a booster dose, MSMPs-S1 significantly increased IgG2a titers and neutralizing antibody levels, exceeding those observed with Al(OH)₃-based formulations. Moreover, MSMPs-S1 enhanced cellular immunity, as indicated by elevated IFN-γ production in CD8⁺ T cells relative to the aluminum-adjuvanted group. In k18-hACE2 transgenic mice, vaccination with MSMPs-S1 conferred protection against a lethal SARS-CoV-2 challenge, with marked reductions in viral loads in both lung and brain tissues. In vitro, stimulation of human peripheral blood mononuclear cells (PBMCs) with MSMPs-S1 led to increased IFN-γ production in CD8⁺ T cells, particularly in the presence of dendritic cells. These findings support the potential of MSMPs as an effective adjuvant capable of promoting both humoral and cellular immunity, with relevance for the development of vaccines targeting emerging viral pathogens.
No takes yet. Share an insight, caveat, or question.
López-Gomez et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: